A U.S. investigation into the lack of write-downs at Exxon Mobil Corp. despite the slump in oil-prices has brought to light the challenge of assessing impairments under U.S. Generally Accepted Accounting Principles (GAAP). But, for international companies and U.S. firms with foreign operations, figuring out GAAP is not the only contest. For the Wall Street Journal’s CFO Journal, I have taken a closer look at write-downs under GAAP vs. IFRS.
Ryanair announces another share buyback, returns over $1.1 billion to investors this year, WSJ
Companies should not be tempted by access to cheap financing, BASF chairman warns, WSJ
Samsung’s Balance Sheet and Brand Reputation Hit by Galaxy Note 7, WSJ
Sports Direct CFO steps down after currency swings result in revenue loss, WSJ
New China Debt-For-Equity Policy Provokes Skepticism, WSJ
City of London Proposes New Regional Visas To Avert Skills Shortage, WSJ
Ahead of Brexit Talks, Companies Puzzle Over the Pound, WSJ
Figuring out GAAP is not the only challenge, WSJ
Bayer’s diligence failure haunts its Monsanto purchase, WSJ
Bayer AG’s failure to identify weaknesses in Merck & Co.’s over the counter drug business before it bought it in 2014 sets a problematic precedent for its latest acquisition, an M&A expert told me today. Why? Read my piece for the Wall Street Journal’s CFO Journal.